The Myriczin/Novartis drug aims to be some kind of “pan-cancer” treatment that works for many different types of cancer, apparently specifically targeting solid tumors. However, the drug is only just moving from the preclinical to the clinical trial phase, so there are still years of trials ahead before we even get a hint of market entry. Novartis paid a good price for just the drug candidates. Hopefully, they still have room to buy the rights to Bex soon as well
6 Likes